GSK agreed to an upfront payment for access to LTZ Therapeutics’ myeloid cell engager (MCE) platform, joining other Big Pharma entrants pursuing myeloid‑directed immune‑engager modalities. The deal signals GSK’s effort to broaden its oncology portfolio into bispecific and engager chemistries that recruit myeloid compartments, a hot area that has drawn interest from Lilly, Novartis, Pfizer and Sanofi. Financial specifics include an initial $50 million upfront; developers and partners expect milestone and royalty structures to follow. The deal highlights the scramble among large drugmakers to secure MCE intellectual property and early‑stage pipelines that could address solid tumors less amenable to T‑cell engagers. Sources: deal announcements and industry reporting.